ABSTRACT
Background
We reviewed the literature on the importance of selected anti-HR-HPV-antibodies (namely16/18 and early oncoproteins, E6 and E7) as potential serological markers for early detection of individuals at high risk of cervical cancer.
Methods
We searched for studies in PubMed and Embase databases published from 2010 to 2020 on antibodies against HR-HPV E6 and E7 early proteins and cervical cancer. Pooled sensitivity and specificity for HPV-16 and -18 antibodies were calculated using a bivariate hierarchical random effect model.
Results
A total of 69 articles were identified; we included 3 studies with 1,550 participants. For the three HPV-16/18 E6 and E7 antibody tests, ELISA based assays had a sensitivity of detecting CIN2+ of 18 % (95% CI:15-21) and specificity of 96% (95% CI:92-98), and for Slot Blot sensitivity was 28.9% (95% CI: 23.3-35.1) and specificity 72% (95% CI:66.6-77.0) of detecting CIN2+ and for Multiplex HPV serology assay ba sed on a glutathione S-transferase (GST) sensitivity was 16% (95% CI:8.45-28.6) and specificity 98% (95% CI:97-99) for detecting ICC.
Conclusion
HR-HPV16/18 E6 and E7 serological markers showed high specificity but sensitivity was suboptimal for the detection of cervical cancer in either population screening settings or as point–of–care screening tests.
This article is protected by copyright. All rights reserved.
No comments:
Post a Comment